Paper41399804
Validation of an algorithm for selection of SGLT2 and DPP4 inhibitor therapies in people with type 2 diabetes across major UK ethnicity groups: a retrospective cohort study.
Güdemann LM and 11 others. Lancet Reg Health Eur, 2026. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Validation of an algorithm for selection of SGLT2 and DPP4 inhibitor therapies in people with type 2 diabetes across major UK ethnicity groups: a retrospective cohort study. Papers, record 41399804. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41399804
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Validation of an algorithm for selection of SGLT2 and DPP4 inhibitor therapies in people with type 2 diabetes across major UK ethnicity groups: a retrospective cohort study.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 24323951 | Completeness and usability of ethnicity data in UK-based primary care and hospital databases. | J Public Health (Oxf) | 2014 | https://conductscience.org/library/papers/24323951 | PubMed |
| 2 | 32821142 | SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients. | Diabetes Metab Syndr Obes | 2020 | https://conductscience.org/library/papers/32821142 | PubMed |
| 3 | 30008267 | Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. | BMC Med | 2018 | https://conductscience.org/library/papers/30008267 | PubMed |
| 4 | 36515129 | Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan. | J Diabetes Investig | 2023 | https://conductscience.org/library/papers/36515129 | PubMed |
| 5 | 36427949 | Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study. | Lancet Digit Health | 2022 | https://conductscience.org/library/papers/36427949 | PubMed |
| 6 | 39427028 | Guidance for unbiased predictive information for healthcare decision-making and equity (GUIDE): considerations when race may be a prognostic factor. | NPJ Digit Med | 2024 | https://conductscience.org/library/papers/39427028 | PubMed |
| 7 | 27891652 | A closed testing procedure to select an appropriate method for updating prediction models. | Stat Med | 2017 | https://conductscience.org/library/papers/27891652 | PubMed |
| 8 | 28834075 | Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review. | Diabetes Obes Metab | 2018 | https://conductscience.org/library/papers/28834075 | PubMed |
| 9 | 38126004 | Use of the CPRD Aurum Database: Insights Gained from New Data Quality Assessments. | Clin Epidemiol | 2023 | https://conductscience.org/library/papers/38126004 | PubMed |
| 10 | 32744394 | Cardiometabolic risk factor control in black and white people in the United States initiating sodium-glucose co-transporter-2 inhibitors: A real-world study. | Diabetes Obes Metab | 2020 | https://conductscience.org/library/papers/32744394 | PubMed |
| 11 | 25043156 | Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on β-cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis. | J Diabetes | 2015 | https://conductscience.org/library/papers/25043156 | PubMed |
| 12 | 36238229 | Weight changes following antidiabetic mediation use: Real-world evidence from health system data. | Obes Sci Pract | 2022 | https://conductscience.org/library/papers/36238229 | PubMed |
| 13 | 37794166 | Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review. | Commun Med (Lond) | 2023 | https://conductscience.org/library/papers/37794166 | PubMed |
| 14 | 32843566 | Precision Medicine in Type 2 Diabetes: Using Individualized Prediction Models to Optimize Selection of Treatment. | Diabetes | 2020 | https://conductscience.org/library/papers/32843566 | PubMed |
| 15 | 29316164 | Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study. | Diabetes Obes Metab | 2018 | https://conductscience.org/library/papers/29316164 | PubMed |
| 16 | 29029369 | No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: A meta-analysis. | J Diabetes Investig | 2018 | https://conductscience.org/library/papers/29029369 | PubMed |
| 17 | 25560730 | Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. | Ann Intern Med | 2015 | https://conductscience.org/library/papers/25560730 | PubMed |
| 18 | 32324082 | Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus. | Curr Med Res Opin | 2020 | https://conductscience.org/library/papers/32324082 | PubMed |
| 19 | 38836934 | Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach. | Diabetologia | 2024 | https://conductscience.org/library/papers/38836934 | PubMed |
| 20 | 23344728 | Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. | Diabetologia | 2013 | https://conductscience.org/library/papers/23344728 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42511477 | Integrated Cytokine, Metabolic, and Proliferative Profiling Reveals Divergent Metabolic and Proliferative Responses in Papillary Thyroid Cancer Cells. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42511477 | PubMed |
| 42502138 | Type 2 diabetes subtypes for precision medicine: methodological challenges and alternative prediction-based approaches. | Diabetologia | 2026 | https://conductscience.org/library/papers/42502138 | PubMed |
| 41952002 | Computational framework to quantify synergistic ligand activity in insulin secretion and resistance pathways in type 2 diabetes. | J Comput Aided Mol Des | 2026 | https://conductscience.org/library/papers/41952002 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| SLC5A2 | 6524 | PubTator's text mining | https://conductscience.org/library/genes/6524 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41399804
GET https://conductscience.org/api/papers/v1/41399804/references?page=2